ScoreWhy is Hinova Pharmaceuticals, Inc. ?
1
Poor Management Efficiency with a low ROCE of 0%
- The company has reported losses and also has negative networth. This is not a good sign for the investors. Either company will have to raise fresh capital or report profits to sustain going forward
2
Poor long term growth as Net Sales has grown by an annual rate of 190.87% and Operating profit at 14.53% over the last 5 years
3
Positive results in Sep 25
- NET SALES(HY) At CNY 23.35 MM has Grown at 21,180.28%
- OPERATING CASH FLOW(Y) Highest at CNY -116.78 MM
- NET PROFIT(HY) Higher at CNY -70.84 MM
4
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 19.46%, its profits have risen by 30.1%
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Hinova Pharmaceuticals, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
No Data Found
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
190.87%
EBIT Growth (5y)
14.53%
EBIT to Interest (avg)
-165.23
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
0.00
Tax Ratio
0.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.19
EV to EBIT
-20.59
EV to EBITDA
-21.33
EV to Capital Employed
14.12
EV to Sales
298.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-68.60%
ROE (Latest)
-14.48%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend19What is working for the Company
NET SALES(HY)
At CNY 23.35 MM has Grown at 21,180.28%
OPERATING CASH FLOW(Y)
Highest at CNY -116.78 MM
NET PROFIT(HY)
Higher at CNY -70.84 MM
ROCE(HY)
Highest at -12.4%
RAW MATERIAL COST(Y)
Fallen by -9,962% (YoY
DEBTORS TURNOVER RATIO(HY)
Highest at 5.59 times
-3What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 11.71 times
Here's what is working for Hinova Pharmaceuticals, Inc.
Net Sales
At CNY 23.35 MM has Grown at 21,180.28%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (CNY MM)
Operating Cash Flow
Highest at CNY -116.78 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Profit
Higher at CNY -70.84 MM
than preceding 12 month period ended Sep 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CNY MM)
Debtors Turnover Ratio
Highest at 5.59 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -9,962% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Hinova Pharmaceuticals, Inc.
Inventory Turnover Ratio
Lowest at 11.71 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
